APA (7th ed.) Citation

X, M., K, P., J, K., P, B., DL, A., MS, W., . . . JS, W. (2024). Efficacy and safety results after >3.5 years of treatment with the Bruton's tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study. Multiple sclerosis (Houndmills, Basingstoke, England), 30(4-5), 558. https://doi.org/10.1177/13524585241234783

Chicago Style (17th ed.) Citation

X, Montalban, et al. "Efficacy and Safety Results After >3.5 Years of Treatment with the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Relapsing Multiple Sclerosis: Long-term Follow-up of a Phase II Randomised Clinical Trial with a Cerebrospinal Fluid Sub-study." Multiple Sclerosis (Houndmills, Basingstoke, England) 30, no. 4-5 (2024): 558. https://doi.org/10.1177/13524585241234783.

MLA (9th ed.) Citation

X, Montalban, et al. "Efficacy and Safety Results After >3.5 Years of Treatment with the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Relapsing Multiple Sclerosis: Long-term Follow-up of a Phase II Randomised Clinical Trial with a Cerebrospinal Fluid Sub-study." Multiple Sclerosis (Houndmills, Basingstoke, England), vol. 30, no. 4-5, 2024, p. 558, https://doi.org/10.1177/13524585241234783.